Because this study entailed a 3-month treatment period and single-stranded AAV.GALGT2 vectors typically take 3–4 weeks after muscle transduction to achieve full gene expression [36], we chose to use the stronger MHCK7 [67, 68] promoter instead of the MCK (CK7-like [69]) promoter, which is currently being tested in a phase 1/2a DMD clinical trial using rAAVrh74.MCK.GALGT2 (NCT03333590). This evidence concerns the gene CKM and Duchenne muscular dystrophy.